Thinking of joining a study?

Register your interest

Become a volunteer?

NCT05560477 | Recruiting | Meniscus Tear

Study to Evaluate the Safety and Efficacy of AM3101 to Augment Meniscal Healing
Sponsor:

University of Cincinnati

Information provided by (Responsible Party):

Brian Grawe

Brief Summary:

The purpose of this clinical trial is to assess the safety and efficacy of AM3101 to facilitate meniscal repair and reduce the incidence of non-healing complications and morbidities associated with a failed meniscal repair. This is a prospective, randomized, controlled, double-blinded, multi-center study.

Condition or disease

Meniscus Tear

Intervention/treatment

AM3101

Saline Placebo

Phase

Phase 1

Phase 2

Detailed Description:

Primary Efficacy Objective: Assess the efficacy of AM3101 by evaluating the integrity of repaired meniscal tissue assessed via MRI at 12 months following injection with AM3101 as compared to the integrity of meniscal tissue at 12 months in the control group injected with a saline solution (placebo). Primary Safety Objective: Assess the safety of AM3101 by evaluating the incidence of individual adverse events and comparing these adverse event rates to incidence rates for the control group injected with a saline solution (placebo). Secondary Objective: Assess and compare functional outcomes in patients receiving AM3101 following meniscal repair to functional outcomes in the control group injected with a saline solution (placebo).}}

Study Type : Interventional
Estimated Enrollment : 74 participants
Masking : Quadruple
Masking Description : A vial of AM3101 is inverted to mix and aspirated into the barrel of a 5cc syringe in a controlled area to ensure sterility. The saline control will be prepared in a similar fashion. The syringes will be labeled with blinding tape and transferred to the surgical suite.
Primary Purpose : Treatment
Official Title : A Prospective, Randomized, Controlled, Double-Blinded, Multi-Center, Phase 1/2b Study to Evaluate the Safety and Efficacy of AM3101 to Augment Meniscal Healing
Actual Study Start Date : April 26, 2023
Estimated Primary Completion Date : January 2024
Estimated Study Completion Date : June 2024
Arm Intervention/treatment

Experimental: Treated with repair and AM3101

Syringe containing AM3101 for injection.

Drug: AM3101

Placebo Comparator: Treated with repair and 0.9% sodium chloride (saline)

Syringe containing commercially available 0.9% sodium chloride for injection.

Drug: Saline Placebo
Ages Eligible for Study: 18 Years to 40 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Criteria
Inclusion Criteria
  • Male or female ≥ 18 and ≤ 40 years old at time of screening.
  • MRI evidence of ACL plus meniscus tear, or isolated meniscus tear.
  • Body mass index (BMI) ≤ 40 kg/m2.
  • Liver and kidney function panels within normal ranges at time of screening
  • Willing and able to comply with the study procedures and visit schedule, and able to follow oral and written instructions.
  • Willing and able to sign an IRB approved informed consent
Exclusion Criteria
  • Have any concomitant ligament injury requiring surgical repair or reconstruction other than the ACL.
  • Have a history of previous meniscus injury that currently needs to be treated or has been treated surgically.
  • Have evidence of arthritis ≥ Grade III (Outerbridge classification) in the affected compartment or greater than Kellgren Lawrence Grade 3.
  • Elevated AST or ALT liver enzymes at time of screening
  • Pregnant or nursing mothers, or women planning on getting pregnant during the time they will be participating in the study.
  • Known drug or alcohol dependence currently or within the last year.
  • Participating concurrently in another clinical study or have participated in a clinical study within the last 90 days, or intend to during the course of the study.
  • Any medical condition or other circumstances that might interfere with the ability to return for follow-up visits in the judgment of the Investigator, including any systemic illness, neuromuscular, neurosensory, or musculoskeletal deficiency that would render the subject unable to perform appropriate postoperative rehabilitation.
  • Any condition which, in the judgment of the Investigator, would preclude adequate evaluation of the investigational product's safety and efficacy.
  • Known allergic reaction to simvastatin.
  • Patients currently taking simvastatin, or any other drug that is within the statin drug classification family.
Study to Evaluate the Safety and Efficacy of AM3101 to Augment Meniscal Healing

Location Details

Please Choose a site

Study to Evaluate the Safety and Efficacy of AM3101 to Augment Meniscal Healing

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Recruiting

United States, Ohio

University of Cincinnati

Cincinnati, Ohio, United States, 45267